CYP19A1 and breast carcinoma: MK-2206 in this class has been recently examined in phase-II clinical trials in combination with the aromatase inhibitor, anasterozole, to treat PIK3CA-mutant ER-positive and HER2-negative breast cancer, with no apparent improvement observed with the combinational treatment [177].